Table 2.
Baseline characteristics of 539 patients in clopidogrel resistance and non-resistance groups
| Parameters | Sample A (N = 239) | Sample B (N = 300) | ||||||
|---|---|---|---|---|---|---|---|---|
| Non-CR (N = 90) |
CR (N = 149) |
P value | Non-CR (N = 98) |
CR (N = 202) |
P value | All patients (N = 539) |
||
| Age (x ± SD) | 61.67 ± 10.67 | 61.08 ± 10.02 | 0.669 | 61.87 ± 10.81 | 60.05 ± 9.61 | 0.143 | 60.94 ± 10.13 | |
| Male, n (%) | 59 (65.6) | 97 (65.1) | 0.943 | 70 (71.4) | 131 (64.9) | 0.256 | 357 (66.2) | |
| Diabetes, n (%) | 14 (17.9) | 29 (25.2) | 0.234 | 15 (20.0) | 32 (17.9) | 0.691 | 90 (16.7) | |
| Hypertension, n (%) | 56 (71.8) | 79 (66.9) | 0.473 | 46 (61.3) | 92 (51.4) | 0.147 | 273 (50.6) | |
| Dyslipidemia, n (%) | 9 (11.4) | 25 (21.7) | 0.063 | 16 (21.3) | 46 (25.7) | 0.460 | 96 (17.8) | |
| Smoking, n (%) | 31 (39.2) | 47 (37.3) | 0.781 | 25 (34.7) | 71 (40.3) | 0.410 | 174 (32.3) | |
| Alcohol use, n (%) | 21 (28.4) | 32 (28.1) | 0.963 | 20 (27.8) | 44 (25.1) | 0.668 | 117 (21.7) | |
| Co-medication | ||||||||
| PPI, n (%) | 47 (56.6) | 74 (54.8) | 0.794 | 41 (41.8) | 78 (38.6) | 0.593 | 240 (44.5) | |
| CCB, n (%) | 23 (27.7) | 28 (20.9) | 0.250 | 6 (6.1) | 0 (0.0) | 0.000 | 57 (10.6) | |
| Statin, n (%) | 51 (61.4) | 71 (53.0) | 0.222 | 21 (21.4) | 0 (0) | 0.000 | 143 (26.5) | |
| Morphine, n (%) | 2 (2.4) | 2 (1.5) | 0.620 | 0 (0.0) | 0 (0.0) | N/A | 4 (0.7) | |
| Platelet count (× 109/L) | 206.85 ± 77.01 | 202.28 ± 63.74 | 0.638 | 106.27 ± 109.76 | 177.87 ± 92.43 | 0.147 | 177.15 ± 94.81 | |
| 300 mg of clopidogrel, n (%) | 41 (45.6) | 78 (52.3) | 0.309 | 47 (48.8) | 105 (52.0) | 0.514 | 271 (50.3) | |
| MPV (fL) | 9.45 ± 3.79 | 9.29 ± 4.05 | 0.761 | 8.06 ± 4.73 | 9.20 ± 4.02 | 0.032 | 9.06 ± 4.15 | |
| PRI (%) | 34.14 ± 11.42 | 67.41 ± 10.89 | 0.000 | 29.89 ± 14.33 | 73.09 ± 10.36 | 0.000 | 57.16 ± 21.90 | |
PPI, proton pump inhibitor; CCB, calcium channel blocker; MPV, mean platelet volume